Muscarinic antipsychotics
Xanomeline-trospium and other muscarinic drugs for schizophrenia.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 8, 2, 6, 11, 11.
All papers from the last 12 months
97 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Cost-effectiveness analysis of xanomeline and trospium chloride for the treatment of adults with schizophrenia in the USJ Med Econ2026 DecPMID 42105309
- Hippocampal mechanisms and neural circuitry of negative symptoms in schizophreniaSchizophr Res2026 NovPMID 42762744
- Correction: "Increasing dopamine synthesis capacity in the dorsal striatum and tonic acetylcholine: implications for the new muscarinic agents in the treatment of schizophrenia"Mol Psychiatry2026 Oct 12PMID 42864378
- Lessons from the history of antipsychotic discovery: part 3 - muscarinic mechanismsBJPsych Bull2026 Oct 8PMID 42843827
- Muscarinic agonists for schizophrenia: Bridging preclinical evidence and clinical enthusiasmBr J Pharmacol2026 OctPMID 42551974Review
- Effects of xanomeline-trospium on the gut-lung microbiota axis and susceptibility to LPS-induced acute lung injury in male and female miceEur Arch Psychiatry Clin Neurosci2026 OctPMID 42400654
- Post-marketing safety surveillance of the novel muscarinic antipsychotic Xanomeline-Trospium for schizophrenia: A comparative disproportionality analysis against olanzapine based on FAERS dataPsychiatry Res2026 OctPMID 42288069
- Early intervention with clozapine: Is there a neurobiological critical period for treatment-resistant schizophrenia?J Psychopharmacol2026 Sep 25PMID 42788527
- Beyond dopamine: KarXT and emerging mechanism-based therapies in schizophreniaFront Psychiatry2026PMID 42846838Review
- Cobenfy (xanomeline-trospium chloride) for schizophrenia: A clinical updateAustralas Psychiatry2026 Sep 15PMID 42741956
More psychiatry trends
All specialties →Gut microbiome and mental health
Links between the gut microbiome and depression or anxiety.
Psilocybin therapy
Psilocybin-assisted therapy for depression and other conditions.
Brain stimulation for depression
Transcranial magnetic stimulation, including accelerated theta-burst protocols, for depression.
Key point: Connectivity- or frequency- and connectivity-individualized accelerated iTBS failed to yield significant antidepressant benefits over sham stimulation in treatment-resistant depression.
MDMA-assisted therapy
MDMA combined with psychotherapy, mainly studied in PTSD.
Ketamine and esketamine for depression
Ketamine and esketamine for treatment-resistant depression.
Neurosteroids for postpartum depression
Zuranolone and brexanolone for postpartum depression.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
(xanomeline[tiab] OR KarXT[tiab] OR emraclidine[tiab] OR muscarinic[tiab]) AND schizophrenia[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.